REVIEW article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1622550
Pyroptosis as a Therapeutic Target in Preeclampsia: Current Research and Future Directions
Provisionally accepted
- 1School of Pharmacy, Guangdong Medical University, Dongguan, Dongguan, China
- 2Southern Medical University,, Dongguan, China
- 3Guangdong Medical University, Zhanjiang, Zhanjiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Preeclampsia (PE) is a severe pregnancy-specific disorder characterized by new-onset hypertension and proteinuria after the 20th week of gestation, posing significant threats to maternal and fetal health. Globally, approximately 4 million women are diagnosed with PE annually, resulting in over 70,000 maternal deaths and 500,000 infant deaths. The exact pathogenesis of PE remains unclear and is associated with multiple factors, including obesity, diabetes, and chronic kidney disease. Pyroptosis, a newly discovered form of programmed cell death, is characterized by plasma membrane rupture and the release of numerous inflammatory mediators. Studies have shown that trophoblast pyroptosis is closely related to PE, potentially hindering trophoblast invasion, causing abnormal remodeling of uterine spiral arteries, and inducing systemic inflammatory responses. 3 * # 1 This review summarizes the latest research progress on the correlation between trophoblast pyroptosis and the pathogenesis of PE. It explores the regulatory roles of NLRP3 Inflammasome,oxidative stress, T helper type 1 (Th1)/T helper type 2 (Th2) cell imbalance, microRNAs and other factors in trophoblast pyroptosis, providing potential targets for the development of early diagnostic biomarkers and therapeutic strategies for PE.
Keywords: Preeclampsia, Trophoblasts, pyroptosis, Inflammation, NLRP3 inflammasome
Received: 06 May 2025; Accepted: 05 Jun 2025.
Copyright: © 2025 Zhu, Xiang, Swamiappan, Li and Peng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
zhongjun Li, Guangdong Medical University, Zhanjiang, Zhanjiang, China
Xinsheng Peng, School of Pharmacy, Guangdong Medical University, Dongguan, Dongguan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.